KoreaTech Today - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTech Today - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Medical

US-Based NeoImmuneTech Targets 96 Billion Won IPO in KOSDAQ

 588 total views,  1 views today

KoreaTechToday Editor by KoreaTechToday Editor
PUBLISHED: February 25, 2021 UPDATED: February 27, 2021
in Medical, South Korea
0
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.

U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.

U.S.-based immunotherapy NeoImmuneTech (NIT) announced last Monday that it plans to raise around 96 billion won ($86.9 million) from its initial public offering (IPO) on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.

NIT said that Mirae Asset Daewoo and Hana Financial Investment would underwrite the deal. Under the plan, the biopharmaceutical company seeks to issue 15 million depository receipts in a price range between 5,400 won ($4.86) and 6,400 won ($5.76). On Wednesday, a book-building process for institutional investors determined the exact share price.

Established in 2014, NIT is a spinoff of Korea-based drug developer Genexine. Genexine owns a 25.31 percent stake in NIT, making it the largest shareholder. Based in Rockville, Maryland, the company has offices in Pangyo and a Research Institute in Pohang, South Korea.

“This IPO opportunity would allow us to further enhance our competitiveness by expanding our already robust clinical program for NT-I7.”

-Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech

Along with an executive team with extensive industry experience, Yang leads the company dedicated to expanding the field of immuno-oncology. Yang founded and invented NIT’s drug candidate NT-17 with the aim of enhancing immunity to infectious diseases.

According to NIT, NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7. It is being studied in multiple clinical trials in solid tumors and infectious diseases (such as COVID-19) and as a vaccine adjuvant. Several of these studies are being conducted under clinical collaboration agreements with global industry leaders in immuno-oncology, including Roche, Bristol Myers Squibb, and Merck.

“We have full confidence in NT-I7’s potential to transform the treatment of cancer, as well as many other diseases where amplifying and improving the functionality of the T cells could provide greater clinical benefit,” said Yang.

Check out other must-read articles from KoreaTechToday:

  • Coupang Files IPO in US for Next-Generation E-commerce Experience
  • Carlyle Group Buys $200 Million Worth Shares of Kakao Mobility
  • North Korea Attempts Pfizer Server Hack for COVID-19 Vaccine Tech
  • COMEUP 2020: COVID-19 Startups: Fighting Against COVID-19
What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: 96 billion wonIPOKOSDAQNeoImmuneTechNIT

Related Posts

South Korea curbs tech leaks to foreign countries
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.
South Korea

South Korea curbs tech leaks to foreign countries

February 8, 2022
Hyundai Rotem set to provide upgraded army tank variants to South Korea
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.
South Korea

Hyundai Rotem set to provide upgraded army tank variants to South Korea

February 2, 2022
S.Korea will track COVID-19 cases with AI-powered facial recognition from January
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.
South Korea

S.Korea will track COVID-19 cases with AI-powered facial recognition from January

December 14, 2021
South Korea sets site engineering standards for big tech firms
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.
Google

South Korea sets site engineering standards for big tech firms

December 9, 2021
National AI complex project starts in South Korea: New AI hub in making
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.
South Korea

National AI complex project starts in South Korea: New AI hub in making

November 25, 2021
Korea to expand bilateral ties with the U.S. to resolve semiconductor shortage
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.
Semiconductor

Korea to expand bilateral ties with the U.S. to resolve semiconductor shortage

November 20, 2021
No Result
View All Result

FREE NEWSLETTER

PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • Top Nine Mobile MMORPG in South Korea for 2020

    0 shares
    Share 0 Tweet 0
  • Top 8 South Korean Mobile MMORPG to Watch Out For in 2021

    0 shares
    Share 0 Tweet 0
  • SKT Popularizes Social VR with Ifland Metaverse Platform

    0 shares
    Share 0 Tweet 0
  • Best Korean Dramas To Watch This 2021

    0 shares
    Share 0 Tweet 0
  • Coway Changes Name After Netmarble’s Aquisition

    0 shares
    Share 0 Tweet 0
  • KT Continues to Accelerate Its ‘Digico’ Transformation

    0 shares
    Share 0 Tweet 0
  • Netmarble to Launch The Seven Deadly Sins: Grand Cross Within the Year

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2021 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy|Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2021 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy|Contact : [email protected] |